GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BiVictriX Therapeutics PLC (LSE:BVX) » Definitions » Insider Ownership

BiVictriX Therapeutics (LSE:BVX) Insider Ownership : 3.47 % (As of May. 03, 2025)


View and export this data going back to 2021. Start your Free Trial

What is BiVictriX Therapeutics Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BiVictriX Therapeutics's insider ownership is 3.47%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BiVictriX Therapeutics's Institutional Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BiVictriX Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.


BiVictriX Therapeutics Insider Ownership Historical Data

The historical data trend for BiVictriX Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BiVictriX Therapeutics Insider Ownership Chart

BiVictriX Therapeutics Historical Data

The historical data trend for BiVictriX Therapeutics can be seen below:

2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31
Insider Ownership 3.47 3.47 3.47 3.47 3.47 3.47 3.47 3.47 3.47 3.47

BiVictriX Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


BiVictriX Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Alderley Edge, Mereside, Alderley Park, Macclesfield, GBR, SK10 4TG
BiVictriX Therapeutics PLC is a drug development company. It has developed its proprietary Bi-Cygni technology which utilizes Antibody Drug Conjugates for the treatment of various cancers including Acute Myeloid Leukaemia. The Group has one reportable segment, being the development of pharmaceutical products within the United Kingdom.

BiVictriX Therapeutics Headlines

No Headlines